Effects of acute treatments with the serotonin 2A antagonist M100907 alone or in combination with the serotonin 2C agonist WAY163909 on methamphetamine self-administration in rhesus monkeys.

Background: Serotonin 5-HT receptor antagonists and 5-HT receptor agonists have been proposed as important candidates for the development of pharmacotherapies for psychostimulant abuse, with evidence suggesting that those receptors may act together to control behavior. However, the role of 5-HT receptors on the reinforcing effects of psychostimulant drugs has not been fully elucidated.

Methods: In the present study, we investigated the effects of the selective 5HT receptor antagonist M100907 alone or in combination with the selective 5HT agonist WAY 163909 on intravenous methamphetamine self-administration in rhesus macaques (N = 3).

Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) and R(-) MDMA on actigraphy-based daytime activity and sleep parameters in rhesus monkeys.

3,4-Methylenedioxymethamphetamine (MDMA) affects monoaminergic pathways that play a critical role in sleep-wake cycles. Dopaminergic mechanisms are thought to mediate the sleep-disrupting effects of stimulant drugs. However, the mechanisms underlying the effects of MDMA on sleep-wake cycles and the effects of (-) MDMA, a stereoisomer that lacks dopaminergic activity, on sleep remain unknown.